BioLight announces Micromedic identifies new genetic markers to predict risk of developing BRONJ, a devastating side effect of certain cancer drugs

BioLight announced today that Micromedic Technologies, BioLight’s cancer diagnostic cluster company, has identified several new genetic markers with high potential to predict necrosis of the jawbone in multiple myeloma patients treated with bisphosphonate drugs.  Upon confirmation of the findings, Micromedic plans to develop a diagnostic assay for use with multiple myeloma and perhaps other patients.

Link to the complete article

Link to Newsroom

Comments are closed